Showing 121 - 140 results of 102,294 for search '(( 5 ((((ppm decrease) OR (nn decrease))) OR (a decrease)) ) OR ( 2 fold decrease ))', query time: 1.51s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  5. 125

    WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression. by Ayana E. Morales (17756335)

    Published 2024
    “…Corresponding densitometry analysis is noted as protein fold expression compared to GAPDH for WT1, p<0.001(***), vFLIP(ns), LANA p<0.05(*), pAKT p<0.05(*), and BCL2 p <0.05(*) using two-sided, unpaired student t-tests. …”
  6. 126
  7. 127

    (R)-albuterol decreases cytokine mRNA levels in activated T cells by Marcela A Ferrada (41716)

    Published 2011
    “…RNA was isolated. Levels of IL-2, IL-13 and IL-6 (A, B, C) were measured by real time PCR. …”
  8. 128
  9. 129

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  10. 130

    Signatures of the Protein Folding Pathway in Two-Dimensional Ultraviolet Spectroscopy by Jun Jiang (149215)

    Published 2015
    “…The complexity of signals decreases as the conformational entropy decreases in the course of the folding process. …”
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135

    HRMECs treated with 3-Deazaneplanocin A (DZNep) chemical inhibitor demonstrated increased miR-200b and decreased VEGF expression. by Michael Anthony Ruiz (726055)

    Published 2015
    “…[NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM D-glucose + 0.05% DMSO, HG+DMSO = 25mM D-glucose + 0.05% DMSO, NG+DZNEP = 5mM D-glucose + 5μM DZNep, HG+DZNEP = 25mM + 5μM DZNep; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to β-actin for VEGF and U6 for miR-200b, expressed as a fold change of NG].…”
  16. 136

    PPM1A directly dephosphorylates STING and TBK1 and prevents STING aggregation. by Zexing Li (713843)

    Published 2015
    “…(D) PPM1A decreases phosphorylation of TBK1 in transfected HEK293 cells. …”
  17. 137
  18. 138
  19. 139
  20. 140